Giant-Cell Arteritis Market Landscape to 2034: Key Forces Shaping the Next Decade of Growth

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Giant-Cell Arteritis Market Size By 2025?
The market size for giant-cell arteritis has seen robust growth in the past few years. It is projected to increase from $1.07 billion in 2024 to $1.12 billion in 2025, representing a compound annual growth rate (CAGR) of 5.3%. Factors contributing to this growth during the historical period include advancements in epidemiological research, genetic knowledge, considerable use of biologics, enhanced diagnostic methods, and the advent of targeted therapies and biologics.

How Big Is the Giant-Cell Arteritis Market Size Expected to Grow by 2029?
Expectations are high for substantial expansion in the giant-cell arteritis market over the coming years. The market size is anticipated to reach $1.36 billion by 2029, with a Compound Annual Growth Rate (CAGR) of 5.0%. The surge projected in this period is underpinned by factors such as increased diagnostic rates, an aging demographic, escalating healthcare spending, patient activism, and geographic expansion. Prominent trends anticipated within this forecast range encompass the advancements in biomarker identification and validation, the creation of therapies aimed at specific molecular pathways, the uptake of cutting-edge imaging systems, breakthroughs in drug delivery, and the employment of AI algorithms for predictive analytics.

View the full report here:
https://www.thebusinessresearchcompany.com/report/giant-cell-arteritis-global-market-report

Which Key Market Drivers Powering Giant-Cell Arteritis Market Expansion and Growth?
The rising focus on personalized healthcare is predicted to drive expansion in the giant-cell arteritis market. Personalized healthcare uses each patient's unique genetic, environmental, and lifestyle factors to shape treatment plans. It has become increasingly common, thanks to advancements in genomics, biotechnology, and data analytics, that allow for the development of targeted therapies that enhance treatment effectiveness and diminish negative outcomes. In the context of giant-cell arteritis (GCA), personalized care can guide treatment choices based on each patient's unique genetic susceptibility, immune profiles, and disease symptoms. The Personalized Medicine Coalition (PMC), a non-profit organization based in the U.S., stated in February 2024 that more than a third of new medicines authorized by the U.S. Food and Drug Administration (FDA) for the fourth consecutive year in 2023 were personalized medicines. The FDA approved 16 new personalized treatments for rare diseases in 2023, a sharp increase from six in 2022. Apart from these, the approvals in 2023 also covered seven cancer drugs and three treatments for other various illnesses. Therefore, the surge in focus on personalized healthcare is believed to be a key driver in the growth of the giant-cell arteritis market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=17162&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Giant-Cell Arteritis Market?
Leading companies in the giant-cell arteritis market are focusing on the creation of new solutions like biosimilar to widen patient treatment choices and cater to unfulfilled healthcare requirements. A biosimilar is a biopharmaceutical product that closely aligns with an already sanctioned biological product without any significant contrasts in safety, purity, and effectiveness. For instance, Tocilizumab-aazg, a biosimilar launched by Fresenius SE & Co. KGaA, a German healthcare company, in the US in April 2024, is intended for the treatment of chronic autoimmune diseases. This therapeutic drug is endorsed for ailments such as rheumatoid arthritis, systemic juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis, and giant-cell arteritis. The approval of this biosimilar was rooted in data acquired from a randomized, double-blind, single-dose, parallel phase 1 trial, which compared its pharmacokinetics, safety, and immunogenicity to tocilizumab reference products from both the US and EU in three separate patient cohorts.

What Are the Emerging Segments in the Giant-Cell Arteritis Market?
The giant-cell arteritis market covered in this report is segmented -

1) By Therapeutics: Prednisone, Methotrexate, Tocilizumab, Aspirin
2) By Mechanism Of Action: Corticosteroids, Immunosuppressive Agents, Anticoagulants, Other Mechanisms Of Action
3) By Route Of Administration: Oral, Intravenous, Subcutaneous, Other Routes Of Administration

Subsegments:
1) By Prednisone: Oral Prednisone, Intravenous (IV) Prednisone, Low-Dose Prednisone Therapy, High-Dose Prednisone Therapy
2) By Methotrexate: Oral Methotrexate, Subcutaneous Methotrexate, Methotrexate Monotherapy, Methotrexate Combination Therapy
3) By Tocilizumab: Intravenous Tocilizumab, Subcutaneous Tocilizumab, Tocilizumab Monotherapy, Tocilizumab In Combination With Corticosteroids
4) By Aspirin: Low-Dose Aspirin Therapy, Aspirin For Cardiovascular Risk Management, Aspirin In Combination Therapy, Enteric-Coated Aspirin

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=17162&type=smp

Who Are the Global Leaders in the Giant-Cell Arteritis Market?
Major companies operating in the giant-cell arteritis market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi SA, Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., CSL Limited, Kiniksa Pharmaceuticals Ltd., MorphoSys AG

Which are the Top Profitable Regional Markets for the Giant-Cell Arteritis Industry?
North America was the largest region in the giant-cell arteritis market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the giant-cell arteritis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=17162

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.